title: A thyroid hormone analogue, triiodothyroacetic acid, corrects corticosteroid-downregulated collagen synthesis.
abstract: The aim of this study was to compare the change in collagen synthesis between topical treatments with two doses of triiodothyroacetic acid (TRIAC), a thyroid hormone analogue, and placebo, after pretreatment with topical betamethasone 17-valerate (BM). Eighteen healthy volunteers were pretreated with BM on abdominal skin for 3 days, and were then treated for 14 days with a cream containing TRIAC (0.03% or 0.1%) or a placebo cream. Collagen production was assessed by quantifying the amino terminal propeptides of human type I and type III procollagen (PINP and PIIINP) in fluids from suction-induced blisters on the treated skin. Three days of treatment with BM led to an average reduction of PINP of 70% and of PIIINP of 50%. Seven days after treatment, the median increase in PINP was 230% (p = 0.03) in the Triac 0.03% group, 148% (p = 0.2) in the TRIAC 0.1% and 5% in the placebo group. The median increase in PINP in the skin area from the start of treatment to the end of treatment was 521% (p = 0.06) in the TRIAC 0.03% group, 339% (p = 0.2) in the TRIAC 0.1% group, and 55% in the placebo group (the p values are related to baseline). Seven days after treatment, the median increase in PIIINP was 24% (p = 0.6) in the Triac 0.03% group, 23% (p = 0.6) in the TRIAC 0.1% group, and -12% in the placebo group. The median increase in PIIINP in the skin area from the start of treatment to the end of treatment was 137% (p = 0.7) in the TRIAC 0.03% group, 230% (p = 0.9) in the TRIAC 0.1% group and 58% in the placebo group (the p values are related to baseline). Histologic examinations of sections from punch biopsies taken at the end of the treatment showed more thickened collagen fibers and increased density of PINP-producing dermal fibroblasts in the TRIAC groups compared to the placebo group. The result suggests a potential role for TRIAC-containing cream concomitant with anti-inflammatory topical treatment with potent glucocorticoids to prevent their suppressive activity on dermal collagen production.
authors.affiliation: Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden.
authors.forename: Parviz
authors.initials: P
authors.lastname: Yazdanparast
authors.forename: Bo
authors.initials: B
authors.lastname: Carlsson
authors.forename: Aarne
authors.initials: A
authors.lastname: Oikarinen
authors.forename: Juha
authors.initials: J
authors.lastname: Risteli
authors.forename: Jan
authors.initials: J
authors.lastname: Faergemann
mesh_terms: D000305:Adrenal Cortex Hormones / Q000502:physiology*; D000328:Adult; D001768:Blister; D003094:Collagen / Q000096:biosynthesis* / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011347:Procollagen / Q000096:biosynthesis / Q000187:drug effects; D012867:Skin / Q000000981:diagnostic imaging; D013396:Suction; D013972:Thyrotropin / Q000097:blood*; D013974:Thyroxine / Q000097:blood*; D014284:Triiodothyronine / Q000031:analogs & derivatives* / Q000097:blood* / Q000494:pharmacology*; D014463:Ultrasonography
chemical_list: D000305:Adrenal Cortex Hormones; D010919:Placebos; D011347:Procollagen; D014284:Triiodothyronine; C010642:3,3',5-triiodothyroacetic acid; D013972:Thyrotropin; D003094:Collagen; D013974:Thyroxine